Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17342
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMartins, Ralph N-
dc.contributor.authorVillemagne, Victor-
dc.contributor.authorSohrabi, Hamid R-
dc.contributor.authorChatterjee, Pratishtha-
dc.contributor.authorShah, Tejal M-
dc.contributor.authorVerdile, Giuseppe-
dc.contributor.authorFraser, Paul-
dc.contributor.authorTaddei, Kevin-
dc.contributor.authorGupta, Veer B-
dc.contributor.authorRainey-Smith, Stephanie R-
dc.contributor.authorHone, Eugene-
dc.contributor.authorPedrini, Steve-
dc.contributor.authorLim, Wei Ling-
dc.contributor.authorMartins, Ian-
dc.contributor.authorFrost, Shaun-
dc.contributor.authorGupta, Sunil-
dc.contributor.authorO'Bryant, Sid-
dc.contributor.authorRembach, Alan-
dc.contributor.authorAmes, David-
dc.contributor.authorEllis, Kathryn-
dc.contributor.authorFuller, Stephanie J-
dc.contributor.authorBrown, Belinda-
dc.contributor.authorGardener, Samantha L-
dc.contributor.authorFernando, Binosha-
dc.contributor.authorBharadwaj, Prashant-
dc.contributor.authorBurnham, Samantha-
dc.contributor.authorLaws, Simon M-
dc.contributor.authorBarron, Anna M-
dc.contributor.authorGoozee, Kathryn-
dc.contributor.authorWahjoepramono, Eka J-
dc.contributor.authorAsih, Prita R-
dc.contributor.authorDoecke, James D-
dc.contributor.authorSalvado, Olivier-
dc.contributor.authorBush, Ashley I-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorGandy, Samuel E-
dc.contributor.authorMasters, Colin L-
dc.date.accessioned2018-04-03T04:56:04Z-
dc.date.available2018-04-03T04:56:04Z-
dc.date.issued2018-
dc.identifier.citationJournal of Alzheimer's disease : JAD 2018; 62(3): 965-992-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17342-
dc.description.abstractWorldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost to the community and government health systems, as well as the stress on families and carers is incalculable. Over three decades of research into this disease have been undertaken by several research groups in Australia, including work by our original research group in Western Australia which was involved in the discovery and sequencing of the amyloid-β peptide (also known as Aβ or A4 peptide) extracted from cerebral amyloid plaques. This review discusses the journey from the discovery of the Aβ peptide in Alzheimer's disease (AD) brain to the establishment of pre-clinical AD using PET amyloid tracers, a method now serving as the gold standard for developing peripheral diagnostic approaches in the blood and the eye. The latter developments for early diagnosis have been largely achieved through the establishment of the Australian Imaging Biomarker and Lifestyle research group that has followed 1,100 Australians for 11 years. AIBL has also been instrumental in providing insight into the role of the major genetic risk factor apolipoprotein E ɛ4, as well as better understanding the role of lifestyle factors particularly diet, physical activity and sleep to cognitive decline and the accumulation of cerebral Aβ.-
dc.language.isoeng-
dc.subjectAlzheimer’s disease-
dc.subject-
dc.subjectamyloid-
dc.subjectapolipoprotein E-
dc.subjectbiomarker-
dc.subjectdementia-
dc.subjectearly diagnosis-
dc.subjectpreclinical-
dc.titleAlzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies.-
dc.typeJournal Article-
dc.identifier.journaltitleJournal of Alzheimer's disease : JAD-
dc.identifier.affiliationCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia-
dc.identifier.affiliationAustralian Alzheimer's Research Foundation, Ralph and Patricia Sarich Neuroscience Research Institute, Nedlands, WA, Australia-
dc.identifier.affiliationDepartment of Biomedical Sciences, Macquarie University, Sydney, NSW, Australia-
dc.identifier.affiliationSchool of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth WA, Australia-
dc.identifier.affiliationKaRa Institute of Neurological Diseases, Sydney NSW, Australia-
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationFlorey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia-
dc.identifier.affiliationCooperative Research Centre for Mental Health, Carlton, Victoria, Australia-
dc.identifier.affiliationSchool of Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University of Technology, Bentley, WA, Australia-
dc.identifier.affiliationTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, ON, Canada-
dc.identifier.affiliationCSIRO Australian e-Health Research Centre/Health and Biosecurity, Perth, WA, Australia-
dc.identifier.affiliationUniversity of North Texas Health Science Centre, Fort Worth, TX, USA-
dc.identifier.affiliationNational Ageing Research Institute, Parkville, Victoria, Australia-
dc.identifier.affiliationUniversity of Melbourne Academic Unit for Psychiatry of Old Age, St George's Hospital, Kew, Victoria, Australia-
dc.identifier.affiliationDepartment of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia-
dc.identifier.affiliationSchool of Psychology and Exercise Science, Murdoch University, Perth, WA, Australia-
dc.identifier.affiliationeHealth, CSIRO Health and Biosecurity, Parkville, Victoria, Australia-
dc.identifier.affiliationCollaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia-
dc.identifier.affiliationLee Kong Chian School of Medicine, Nanyang Technological University, Singapore-
dc.identifier.affiliationCSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia-
dc.identifier.affiliationDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA-
dc.identifier.doi10.3233/JAD-171145-
dc.identifier.orcid0000-0003-3910-2453-
dc.identifier.pubmedid29562546-
dc.type.austinJournal Article-
local.name.researcherMasters, Colin L
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

42
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.